ClinicalTrials.gg
TerminatedNCT04070313Updated Dec 6, 2021

A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan

A Phase 2 interventional study of S-1 in Resected Pancreatic Cancer, Pancreatic Cancer and Adjuvant Chemotherapy, sponsored by TTY Biopharm. Terminated at 4 sites in Taiwan. Per ClinicalTrials.gov, last updated 2021-12-06.

Sponsored by TTY Biopharm · Phase 2, Interventional, and Treatment

Why this study was terminated
Study treatment is to use TS-1 (mono-chemotherapy agent) in adjuvant setting for pancreatic cancer, which may be less clinical benefit compared to combination therapy according to current trend at investigators' discretion.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing tegafur in Pancreatic Neoplasms — 3 open to participants now, 3 under way, none of them phase 3. Tegafur · Pancreatic Neoplasms.

Enrollment
21st of 25
36 · median 60
Started
2019
with 5 others
Phase 2
21 of 26
2 open now
Registered
23rd of 26
by date

Among the 26 studies testing tegafur in Pancreatic Neoplasms, this one is the 21st largest by enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2019, is one of 21 in phase 2, and was the 23rd registered.

Pancreatic Neoplasms

3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

3 of the 26 studies testing tegafur in Pancreatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tegafur

Tegafur: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 745 Pancreatic Neoplasms studies recruiting now, 478 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tegafur in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

To verify the efficacy of S-1 adjuvant chemotherapy in resectable pancreatic cancer.

  • Primary Endpoint: Relapse-free survival (RFS)
  • Secondary Endpoints: 2-year survival rate, 2-year relapse-free survival (RFS) rate, safety profile
03

Conditions studied

  • Resected Pancreatic Cancer
  • Pancreatic Cancer
  • Adjuvant Chemotherapy
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with resected adenocarcinoma pancreatic cancer that was verified.
  2. Patients with macroscopic total resection of the primary tumor, and confirmed local residual tumor classified as R0/R1.
  3. Absence of distant and malignant ascites
  4. Adequate oral intake
  5. Age of 20 years or above
  6. (ECOG) Performance Status (PS) of 0 or1
  7. Adequate hematopoietic which is defined as below,

    • White blood cell count: 3,000/mm3, ≤ 12,000/mm3
    • count: 100,000/mm3
    • : 8.0 g/dL
    • ANC: 1500/mm3
  8. CA19-9 ≤ 100 U/mL
  9. Absence used of chemotherapy or radiotherapy
  10. Within 10 weeks following resection of pancreatic cancer
  11. Written given

Exclusion criteria

Exclusion Criteria:

  1. Patient previously received therapy for pancreatic cancer
  2. Patient previously received S-1 treatment and concurrent using other fluoropyrimidine-group anti-cancer drugs, combination therapies with them (such as folinate plus Tegafur-Uracil combination therapy)
  3. Recurrence prior to registration
  4. Moderate or more severe pleural effusion or ascites upon abdominal CT
  5. Inadequate hepatic function which is defined as below:

    • Total greater than 1.5 times the
    • (AST) or alanine aminotransferase (ALT)greater than 2.5 times the ULN
  6. Inadequate renal function which is defined as below:

    rate (CCr) \< 60 mL/min

  7. Heart failure of Class III (Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea.) or Class IV (Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases.) according to the functional classification
  8. Other serious complications such as active peptic ulcer, paresis of intestine or any others
  9. Pulmonary fibrosis or interstitial pneumonia clearly observed
  10. Uncontrolled watery diarrhea Whether a patient has diarrhea 4 or more times a day while receiving adequate supportive therapy will be used as the indicator to determine whether watery diarrhea is inadequately controlled.
  11. Blood transfusion within 2 weeks prior to registration
  12. Myocardial infarction within 6 months following documentation of pancreatic cancer
  13. An active infectious disease (pyrexia of 38°C or higher, etc.), including active or C.

    • Active HBV: HBeAg positive or HBeAg negative but HBV DNA > 2000 IU/mL.
    • Active : Anti-HCV Ab positive
  14. Poorly controlled diabetes mellitus:

    Fasting blood sugar ≥ 200 mg/dL or ≥ 10.0 %

  15. Participation in the study by the patient is judged difficult due to a complicating psychiatric disorder or psychological symptoms
  16. Patient is using drainage.
  17. Serious drug allergy or to the ingredients of S-1
  18. Other with the exception of non-melanoma skin cancer or cervical carcinoma in situ within 5 years prior to registration
  19. Pregnant women or nursing mothers, or positive pregnancy test for women of . Fertile women of childbearing potential unless using a reliable and appropriate method throughout the treatment period and for three months following cessation of treatment.
  20. Man who is willing to conceive a child during the treatment period.
  21. On flucytosine, phenytoin or warfarin potassium treatment.
  22. Participation in another clinical trial with any drug within 30 days prior to registration.
  23. Patients who were judged to be ineligible as the subjects of this study by the investigators
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    S-1

    single-arm

    Drug: S-1

Interventions

  • DrugS-1

    Drug pages: Tegafur · Gimeracil · Oxonic Acid

    Eligible patients will receive S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 28 in a 6-week cycle.

06

What researchers measure

Primary outcomes

  1. Relapse-free survival (RFS)

    The time from registration to the time of initial detection of relapse or death from any causewhichever came first, assessed up to 2 years

    Time frame: 2 years

Secondary outcomes

  1. 2-year survival rate

    The number of patient who occur relapse or death from any cause, whichever comes first before end of 2 years

    Time frame: 2 years

  2. 2-year relapse-free survival (RFS) rate

    the percentage of people in a study who are alive 2 years after their diagnosis or the start of treatment

    Time frame: 2 years

  3. safety profile

    The incidence and percentage of patients with at least one occurrence of preferred term will be included,according to the most severe NCI-CTCAE v5.0 grade

    Time frame: 2 years

07

Study locations

4 sites
  • Chang Gung Memorial Hospital_Linkou
    Linkou, Taiwan
  • National Cheng Kung University Hospital
    Tainan, Taiwan
  • National Taiwan University Hospital
    Taipei, Taiwan
  • Taipei Veterans General Hospital, Taiwan
    Taipei, Taiwan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Oct 2021, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2019
First posted
Aug 28, 2019
StartActual
Jul 11, 2019
Primary completionActual
Oct 31, 2021
CompletionActual
Oct 31, 2021
Last update
Dec 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04070313
Lead sponsor
TTY Biopharm
Responsible party
Sponsor
First posted
Aug 28, 2019
Start date
Jul 11, 2019
Primary completion
Oct 31, 2021
Completion
Oct 31, 2021
Last update
Dec 6, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tegafur · Gimeracil · Oxonic Acid

Start the discussion